Patients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment; muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on MEK treatment
Patients who are planning on embarking on a new strenuous exercise regimen after initiation of study treatment; note: muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided whilst on sonidegib study treatment
Patients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment; nota bene (NB): muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on MEK treatment
Patients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment; muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on MEK treatment
Subjects planning on embarking on a new strenuous exercise regimen after first dose of study treatment that can result in significant increases in plasma CK levels
Started or planning to start on strenuous exercise regimen after first dose of study treatment (i.e., muscular activities, such as strenuous exercise, that can result in significant increase in plasma CK levels should be avoided while on trametinib treatment)
Planning to embark on a new strenuous exercise regimen after first dose of study treatment; NOTE: muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on binimetinib treatment
Patients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment; NB: muscular activities, such as strenuous exercise, that can result in significant increases in plasma creatine kinase (CK) levels should be avoided while on MEK treatment
Patients who have neuromuscular disorders (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on concomitant treatment with drugs that are recognized to cause rhabdomyolysis, such as -hydroxy--methylglutaryl (HMG) coenzyme A (CoA) inhibitors (statins), clofibrate and gemfibrozil, and that cannot be discontinued at least  weeks prior to starting LDE treatment; patients who are planning on embarking on a new strenuous exercise regimen after initiation of study treatment, should also be excluded; muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided whilst on LDE treatment
Patients who are planning on embarking on a new strenuous exercise regimen after initiation of study treatment; NOTE: muscular activities, such as strenuous exercise, that can result in significant increases in plasma creatine kinase (CK) levels should be avoided whilst on LDE treatment
Patients who are planning on embarking on a new strenuous exercise regimen after initiation of study treatment; note that muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on LDE treatment
Patients who are planning on embarking on a new strenuous exercise regimen after initiation of study treatment; muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided whilst on sonidegib treatment
Patients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment; muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on MEK treatment
Patients who have neuromuscular or muscular disorders (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on concomitant treatment with drugs that are known to cause rhabdomyolysis (such as statins and fibrates), and that cannot be discontinued at least  weeks prior to starting LDE; if it is essential that the patient stays on a statin for hyperlipidemia, only pravastatin may be used with extra caution; patients should not plan to embark on a new strenuous exercise regimen after initiation of study treatment; (nota bene [NB]: muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided whilst on LDE treatment)
Patients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment; NB: muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on MEK treatment
Patients who are planning on embarking on a new strenuous exercise regimen that can result in significant increases in plasma creatine kinase (CK) levels
Patients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment; muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on MEK treatment
Patients who have neuromuscular disorders (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on concomitant treatment with drugs that are recognized to cause rhabdomyolysis, such as -hydroxy--methylglutaryl-coenzyme A (HMG CoA) inhibitors (statins), clofibrate and gemfibrozil, and that cannot be discontinued at least  weeks prior to starting LDE treatment; if it is essential that the patient stays on a statin to control hyperlipidemia, only pravastatin may be used with extra caution\r\n* Patients who are planning on embarking on a new strenuous exercise regimen after initiation of study treatment; NB: muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided whilst on LDE treatment